Multiple sclerosis during adalimumab treatment in a case with ankylosing spondylitis.

Abstract

Ankylosing spondylitis is a chronic and progressive inflammatory disease involving the sacroiliac joints with HLA-B27 positivity in 85% of the patients and radiologically evidence of sacroiliitis. It is associated with several extraarticular manifestations, but neurological complications are rare. Occurrence of multiple sclerosis in patients with ankylosing spondylitis has been reported in limited cases. Adalimumab, a TNF-α antagonist, offers a significant improvement in ankylosing spondylitis and is considered to be less immunogenic and more tolerable than other TNF-α blockers. A case of multiple sclerosis coexisted with HLA-B27 positive ankylosing spondylitis after treated with adalimumab was reported.

• Authors: Uğur Uygunoğlu, Derya Uluduz, Koray Taşçılar, Sabahattin Saip
• Journal: Rheumatology international (Rheumatol Int) Vol. 34 Issue 1 Pg. 141-3 (Jan 2014) ISSN: 1437-160X [Electronic] Germany
• PMID: 23269571 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• HLA-B27 Antigen
• Immunosuppressive Agents
• Adalimumab

Topics

• Adalimumab
• Adult
• Antibodies, Monoclonal, Humanized (adverse effects)
• HLA-B27 Antigen (immunology)
• Humans
• Immunosuppressive Agents (adverse effects)
• Male
• Multiple Sclerosis (chemically induced, diagnosis, immunology)
• Risk Factors
• Spondylitis, Ankylosing (diagnosis, drug therapy, immunology)
• Time Factors
• Treatment Outcome